AmerisourceBergen Oncology Drug Repackaging Program Draws $260m Fine
Executive Summary
Now-defunct AmerisourceBergen subsidiary inappropriately repackaged oncology support drugs like Neupogen and Procrit in pre-filled syringes, violating the law and prompting safety concerns, Department of Justice announced.
You may also be interested in...
AmerisourceBergen Settlement On Injectable Drug Repackaging Includes Forfeiture Of Exec Pay
Corporate integrity agreement attached to second DOJ settlement over repackaging of injectable cancer drugs would require recoupment of exec performance pay following misconduct.
FDA Works To Encourage Office-Use Compounding In Advance Of Legislation
FDA looks to carve out a place for office-use compounding within Section 503B, the new framework created after deadly fungal contamination of products, while industry supports efforts in Congress to allow it under the traditional Section 503A.
Curbing Cancer Drug Costs: Lartruvo Vial Sizes Designed To Reduce Waste
Lilly researchers used real-world data to identify a second vial size for Lartruvo that could reduce waste by nearly 87% compared to offering only a single large-size vial.